Cannabis cultivation for research is the topic of a seminar at UFSM
Follow the main news about cannabis cultivation, Anvisa regulation, science, and business in Brazil. Visit the Sechat portal and check it out!
The debate on cannabis cultivation for research gains prominence at the Universidade Federal de Santa Maria (UFSM) with the seminar "Challenges and Opportunities of Cannabis Cultivation for Research", bringing together specialists, researchers, the productive sector, and patient associations.
The event takes place at the Flávio Miguel Schneider Auditorium, located in the Rural Sciences Center (CCR/UFSM), from 8:30 a.m. to 6:00 p.m. The initiative seeks to position the institution as a hub for scientific development, biopharmaceutical innovation, and technology transfer within the new national regulatory framework.
In this article you will see:
- How Anvisa's new regulatory framework impacts universities
- UFSM's potential in research and the veterinary market
- International integration in the Southern Cone and industrial hemp
- The therapeutic role of associations and the business ecosystem
- How to register for the seminar
What changes with Anvisa's new regulatory framework for cultivation?
The technical schedule begins with in-depth discussions on the new guidelines of the Agência Nacional de Vigilância Sanitária (Anvisa) aimed at special authorization for the cultivation of Cannabis sativa strictly for scientific and medicinal purposes.
The panel addresses how public higher education institutions and research centers can apply for and access special licenses, ensuring legal certainty, traceability, and sanitary compliance at all stages of the development chain.
How does scientific research drive innovation and the veterinary market?
In the panel dedicated to UFSM's multidisciplinary potential, researchers discuss the main agronomic and phytotechnic challenges and analytical processes for the standardization of high-precision plant extracts.
In addition to human health applications, the meeting highlights emerging opportunities such as the pet cannabinoid market, technology transfer to the productive sector, and the protection of intellectual property generated within academic laboratories.
Advances in the Southern Cone and the potential of industrial hemp
International cooperation and the exchange of regulatory experiences with neighboring Latin American countries are also part of the seminar's central agenda.
The debate analyzes regulatory successes and failures in the development of phytotherapeutics and the utilization of industrial hemp, evaluating how Rio Grande do Sul and Brazil can competitively integrate into these scientific and commercial cooperation networks.
What is the therapeutic role of patient associations and startups?
Patient support, guaranteeing the fundamental right to health, and the transition from the informal market to the Anvisa-regulated model conclude the event's thematic schedule.
Specialists and managers analyze the expanding business ecosystem, the connection between agricultural input suppliers, biotechnology startups, and associative entities working directly to support phytocannabinoid-based treatments. Concurrently, the event features an Innovation and Technology Showcase with booths from companies and associations.
How to pre-register for the seminar at UFSM?
Participation in the event is open to students, healthcare professionals, agronomists, researchers, and the external community. Admission is charitable, through the donation of 2 kg of non-perishable food at the venue.
- Location: Flávio Miguel Schneider Auditorium – Rural Sciences Center (CCR) / UFSM
- Time: From 8:30 a.m. to 6:00 p.m.
- Online Registration: Access the official page at
ufsm.br/eventos/cannabis2026or fill out the institutional accreditation form.
Institutional Sources and References:
- Universidade Federal de Santa Maria (UFSM) – Rural Sciences Center (CCR). Official Schedule: Challenges and Opportunities of Cannabis Cultivation for Research.
- Agência Nacional de Vigilância Sanitária (Anvisa) – Guidelines and Resolutions on special authorization for research and medicinal purposes with Cannabis sativa L.